Elan (ELN) Up Following Positive TYSABRI Study Results On Reversing MS Damage
More News related to BIIB
- Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia
- Biogen Idec to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
More News related to ELN
- Elan to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Elan Corporation Plc Announces Expiration of Tender Offer for 73/4% Senior Fixed Rate Notes Due 2011
- UBS Downgrades Elan (ELN) to Neutral
- Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Reduces Rates of Hospitalization in Patients with Moderate-to-Severe Crohn's Disease
- Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com
Shares of Elan (NYSE: ELN) are up 8% this AM after the company and partner Biogen Idec (NASDAQ: BIIB) announced results of a study demonstrating that TYSABRI promoted regeneration and stabilization of damage done to the myelin sheath due to symptoms of multiple sclerosis.
The companies said additional posters will also be presented during the Congress highlighting the ability of TYSABRI, in some patients, to improve physical function and patient reported outcomes on cognition, quality of life, and fatigue. TYSABRI is the first approved MS therapy with reported data suggesting that some of the signs of disease progression can be stopped. The strong efficacy profile demonstrated in clinical trials is enhanced further from these data and may help redefine success in MS.
Related Categories
FDAInsiders' Blog
Momentum Movers
Stocks Mentioned
+0.53
-0.18Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
